Full Text
The Full Text of this article is available as a PDF (65.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Degos F., Christidis C., Ganne-Carrie N., Farmachidi J. P., Degott C., Guettier C., Trinchet J. C., Beaugrand M., Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000 Jul;47(1):131–136. doi: 10.1136/gut.47.1.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., Nevens F., Solinas A., Mura D., Brouwer J. T. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb;112(2):463–472. doi: 10.1053/gast.1997.v112.pm9024300. [DOI] [PubMed] [Google Scholar]
- Imai Y., Kawata S., Tamura S., Yabuuchi I., Noda S., Inada M., Maeda Y., Shirai Y., Fukuzaki T., Kaji I. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998 Jul 15;129(2):94–99. doi: 10.7326/0003-4819-129-2-199807150-00005. [DOI] [PubMed] [Google Scholar]
- Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., Iijima A., Urushihara A., Kiyosawa K., Okuda M. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998 May;27(5):1394–1402. doi: 10.1002/hep.510270529. [DOI] [PubMed] [Google Scholar]
- Mazzella G., Accogli E., Sottili S., Festi D., Orsini M., Salzetta A., Novelli V., Cipolla A., Fabbri C., Pezzoli A. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996 Feb;24(2):141–147. doi: 10.1016/s0168-8278(96)80022-5. [DOI] [PubMed] [Google Scholar]
- Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., Shiomi S., Seki S., Kobayashi K., Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995 Oct 21;346(8982):1051–1055. doi: 10.1016/s0140-6736(95)91739-x. [DOI] [PubMed] [Google Scholar]
- Seeff L. B., Miller R. N., Rabkin C. S., Buskell-Bales Z., Straley-Eason K. D., Smoak B. L., Johnson L. D., Lee S. R., Kaplan E. L. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000 Jan 18;132(2):105–111. doi: 10.7326/0003-4819-132-2-200001180-00003. [DOI] [PubMed] [Google Scholar]
- Serfaty L., Aumaître H., Chazouillères O., Bonnand A. M., Rosmorduc O., Poupon R. E., Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998 May;27(5):1435–1440. doi: 10.1002/hep.510270535. [DOI] [PubMed] [Google Scholar]
- Valla D. C., Chevallier M., Marcellin P., Payen J. L., Trepo C., Fonck M., Bourliere M., Boucher E., Miguet J. P., Parlier D. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999 Jun;29(6):1870–1875. doi: 10.1002/hep.510290616. [DOI] [PubMed] [Google Scholar]